Kaplan Fox Encourages Investors of Smartsheet Inc. (NYSE: SMAR) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026

A class action lawsuit was filed against Smartsheet (NYSE: SMAR) by sellers who purchased between June 1, 2024 and September 23, 2024, alleging the company repurchased its shares while knowing of a formal acquisition offer from a Blackstone–Vista Consortium at prices “significantly above” the then-current market. The complaint claims Smartsheet failed to disclose the acquisition offer, or should have stopped buybacks, potentially overcharging investors versus what the company paid for shares. This is a litigation overhang rather than a confirmed financial result, but it could add uncertainty around disclosures and buyback practices.

Analysis

This is a legal overhang, not an operating thesis. The economic leakage from a post-deal securities claim typically accrues to insurers and legal advisors first; any direct impact on BX is likely de minimis unless discovery exposes process failures that threaten future deal economics. If the market sells sponsor-backed software names on headline risk, that is more likely a short-lived sentiment trade than a re-rating event.

The more interesting second-order effect is on future private-equity bidding discipline in software. Sponsors may demand tighter reps, more explicit disclosure controls, and wider legal escrows, which can modestly raise transaction friction and reduce aggressiveness at the margin over 6-18 months. That matters for new take-privates, but it should not meaningfully alter earnings power for TEAM, MNDY, or ASAN unless the story widens into a broader governance scare.

The contrarian view is that litigation headlines are often over-discounted relative to their actual settlement value. If there is no durable, nonpublic evidence trail, this is likely a nuisance claim with limited multiple impact and a finite timeline. The key falsifiers are a surviving motion-to-dismiss, damaging discovery, or any extension of the alleged knowledge window; absent those, any price reaction should fade within days rather than months.

Key Decisions for Investors

• Do not short BX on this headline; if it sells off >1% on no fundamental news, use it as a 1-3 day mean-reversion buy with a tight stop if the complaint broadens into sponsor-wide process issues.
• No direct trade in SMAR unless there is a live, tradeable residual security; if it exists, fade any headline-driven bounce rather than chase it long.
• Keep TEAM / MNDY / ASAN on a watchlist for sympathy weakness; only buy if the sector is hit >2% on litigation noise while business fundamentals remain unchanged.
• Revisit the thesis only after motion-to-dismiss and discovery milestones; a surviving claim or adverse document production would be the first point where legal risk becomes valuation-relevant.